Artrya Limited (ASX:AYA)
Artrya Limited (ASX:AYA) is a medical technology company leading the world in cardiac image assessment.
The Company's ground-breaking, non-invasive solution - Salix - uses AI to detect and assess the superior predictor of heart attack, Vulnerable Plaque. Artrya's comprehensive cardiac-health report provides efficient and accurate diagnostic support to radiologists and cardiologists. It enables clinicians to triage patients and identify individuals at high risk of heart attack at a glance.
Salix offers precision medicine for cardiac care. This means a world where patients acknowledge and react to the Company's early warning system and engage with healthcare treatment plans to potentially reduce their heart attack risk.
Heart disease is responsible for one in three deaths globally. Coronary artery disease affects around 126 million individuals and results in nine million deaths each year. This costs the United States economy more than $200 billion annually.
Artryas Salix will focus on the most advanced diagnostic procedures, the 26 million coronary computed tomography angiography scans conducted each year.